Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93730Research ArticleAntagonisty retseptorov k angiotenzinu II: obzor effektivnosti i bezopasnostiEreminaYu. N-LeonovaM. V-GalitskiyA. A-15012013151252928122021Copyright © 2013, Consilium Medicum2013артериальная гипертензияантагонисты рецепторов ангиотензинасартаны[Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003; 7: 1–94.][Nixon R.M., Muller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta - analytical approach. Int J Clin Pract 2009; 63 (5): 766–75.][Neutel J et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997; 19: 447–58.][Sawada T et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks. KYOTO HEART Study Eur Heart J 2009; 30 (20): 2461–9.][Thürmann P.A., Kenedi P, Schmidt A. et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037–42.][Picca M, Agozzino F, Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004; 21: 76–86.][Dahlof B, Devereux R.B.., Kristiansson K. et al. LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study: a randomized trial against atenolol. Lancet 2002; 359: 995–1003.][Schmidt and Schmieder. Hypertension and LVH: How much attention should we pay to the RAAS. Dialogues on Cardiovascular Medicine 2005; 10 (1): 36.][Robert H. Fagard, Hilde Celis, Lutgarde Thijs and Stijn Wouters. Regression of left ventricular mass by antihypertensive Tteatment: a meta - analysis of randomized comparative studies. Hypertension 2009; 54: 1084–91.][Wachtell K. et al. Angiotensin II receptor blockade reduces new - onset atrial fibrillation and subsequent stroke cmpared to atenolol. The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol 2005; 45: 712–9.][Eijkelkamp W.B., Zhang Z, Remuzzi G. et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18 (5): 1540–6.][Burgess E, Bakris G, Weir M, Koval S. Comparative long term effects of two AT 1 receptor blockers on proteinuria in patients with type-2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial. J Hypertens 2007; 25 (Suppl. 2): S27.][Haller H, Ito S, Izzo J.L. et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 9907.][Kunz R, Friedrich C, Wolbers M, Mann J.F.E. Meta - analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med 2008; 148: 30–48.][Xie Q.Y., Wang Y.J., Sun Z.L., Yang T.L. Effects of valsartan and indapamide on plasma cytokines in essential hypertension. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006; 31 (5): 629–34.][Manabe S, Okura T, Watanabe S. et al. Effects of angiotensin II receptor blockade with valsartan on pro - inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46 (6): 735–9.][Nakamura T, Fujii S, Hoshino J. et al. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28 (12): 937–43.][Lewington S, Clarke R, Qizilbash N et al. Age - specific relevance of usual blood pressure to vascular mortality: a meta - analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 2002; 360: 1903–13.][Turnbull F. Blood Pressure Lowering Treatment Trialists\' Collaboration Effects of different blood - pressure - lowering regimens on major cardiovascular events: results of prospectively - designed overviews of randomised trials. Lancet 2003; 362: 1527–35.][Blood Pressure Lowering Treatment Trialists\' Collaboration. Blood pressure - dependent and independent effects of agents that inhibit the renin - angiotensin system. J Hypertens 2007; 25: 951–8.][Julius S, Kjeldsen S.E., Weber M. et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.][Yusuf S, Diener H.C., Sacco R.L. et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N Engl J Med 2008; 359 (12): 1225–37.][Bangalore S, Parkar S, Grossman E, Messerli F.H. A meta - analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new - onset diabetes mellitus. Am J Cardiol 2007; 100 (8): 1254–62.][Sipahi I, Debanne S.M., Rowland D.Y. et al. Angiotensin - receptor blockade and risk of cancer: meta - analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627–36.][Coleman C.I., Baker W.L., Kluger J, White C.M. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta - analysis of randomized controlled trials. J Hypertens 2008; 26 (4): 622–9.][Chin H.J., Oh S.W., Goo H.S. et al. and members of the PREMIER Group Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis. J Korean Med Sci 2011; 26 (1): 59–66.][FDA Drug Safety Communication: Ongoing safety review of the angiotensin receptor blockers and cancer 2010.][Bramlage P and Hasford J. Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany. Institutfür Medizinische Informations verarbeitung, Biometrie und Epidemiologie, University of Munich, Germany. Cardiovasc Diabetol 2009; 8: 18.][Ferrario C.M., Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens (Greenwich) 2002; 4 (6): 424–32.][Fogari R, Corradi I, Poletti L. et al. Sexual activity in hypertensive emales treated with valsartan or carvedilol. A cross - over study. J Hypertens 1999;17 (Suppl. 3): S65.]